Arcoxia - instructions, indications, composition, side effects

Active Ingredient: Etoricoxib

Excipients: May include calcium hydrogen phosphate, croscarmellose sodium, magnesium stearate, lactose monohydrate, hypromellose, titanium dioxide, glycerol triacetate, and other inactive ingredients depending on the formulation.

Tablets: Available in various strengths, including 60 mg, 90 mg, and 120 mg tablets.

Arcoxia belongs to the pharmacological group of selective cyclooxygenase-2 (COX-2) inhibitors (ATC code: M01A H05).

Pharmacodynamics: Etoricoxib exhibits anti-inflammatory, analgesic, and antipyretic effects by selectively inhibiting the enzyme cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in pain and inflammation.

Pharmacokinetics: Following oral administration, etoricoxib is rapidly absorbed from the gastrointestinal tract. It undergoes extensive metabolism in the liver and is primarily eliminated through biliary excretion.

Arcoxia is indicated for the relief of:

• Acute and chronic pain associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
• Acute gouty arthritis
• Management of acute pain and primary dysmenorrhea

Arcoxia is contraindicated in individuals with a history of hypersensitivity to etoricoxib or other selective COX-2 inhibitors, as well as those with active peptic ulcer disease, severe heart failure, severe hepatic impairment, or established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.

Arcoxia may interact with other medications, including anticoagulants, antiplatelet drugs, angiotensin-converting enzyme (ACE) inhibitors, diuretics, and lithium, potentially increasing the risk of bleeding or adverse effects. Caution is advised when co-administering Arcoxia with other drugs.

Arcoxia tablets should be taken orally with a full glass of water. The dosage and duration of therapy should be individualized based on the patient’s condition, response to treatment, and risk factors for adverse effects. It is recommended to take Arcoxia with food to reduce the risk of gastrointestinal irritation.

Arcoxia is not recommended during pregnancy or breastfeeding due to the potential risk of fetal harm and excretion in breast milk. Women of childbearing potential should use effective contraception during treatment with Arcoxia.

Arcoxia may cause dizziness or drowsiness in some patients. Therefore, caution is advised when driving or operating machinery, especially during the initiation of therapy or following dosage adjustments.

The recommended dosage of Arcoxia varies depending on the indication, severity of pain, and patient factors. Healthcare providers will determine the appropriate dose and treatment duration based on clinical judgment and guidelines.

In the event of an overdose, supportive measures should be initiated as needed. Arcoxia overdoses may lead to symptoms such as gastrointestinal irritation, nausea, vomiting, and renal impairment. Immediate medical attention is required in cases of overdose.

Common side effects of Arcoxia may include gastrointestinal disturbances (e.g., dyspepsia, abdominal pain), headache, dizziness, and peripheral edema. Serious adverse effects such as cardiovascular events, hepatic toxicity, and renal impairment are rare but may occur, especially with prolonged use or at high doses.

Arcoxia tablets should be stored at room temperature (15-30°C) in a dry place, protected from light and moisture. Keep out of reach of children. Check the expiration date on the packaging and discard any expired or unused medication.

These extended instructions provide comprehensive information on the composition, pharmacological properties, indications, contraindications, interactions, administration, side effects, storage, and usage of Arcoxia, aiding healthcare professionals and patients in safe and effective pain management. Always consult a healthcare provider for personalized medical advice.